Industry Outlook

Genetic Testing market accounted for USD 22.3 Billion in 2024 and is expected to reach USD 65.5 Billion by 2035, growing at a CAGR of around 10.3% between 2025 and 2035. The genetic testing market is expanding due to the increasing need for personalized medicines and technological advancements. The genetic disorders are identified in genetic testing techniques by analyzing DNA, RNA, or proteins, and the risks are evaluated. Genetic diseases are increasing with people becoming more aware to genetic disorders. Next-generation sequencing and gene testing help to improve test accuracy and lower the cost of treatment. Many companies are ruling the direct-to-consumer testing market where patients can conduct genetic testing at home.

Report Scope:

Market Dynamics

Increasing occurrence of genetic and rare diseases

The genetic and rare disease prevalence is increasing due to improved diagnosis and genetic mutation rates. The advancement in technology helps to improve the accuracy. The environmental factor may lead to the risk of rare diseases. More cases are reported because of increasing awareness about the genetic diseases. The rise in consanguineous marriages leads to inherited genetic disorders. As people are living longer, age-related mutations are likely to be observed. Over 7,000 rare diseases affect more than 30 million people in the United States. Many rare conditions are life-threatening and most do not have treatments. Drug, biological, and device development in rare diseases is challenging for many reasons, including complex biology and the lack of understanding of the natural history of many rare diseases.

Ethical and societal implications of genetic testing.

The most significant hindering restraint is the ethical considerations and implications of genetic testing. The ethical and moral dilemmas arise due to genetic discrimination. The genetic tasks are complicated and there are more chances of misinterpreting of results. The major concern is the privacy of genetic information as there are also ethical considerations. Individuals are not fully able to understand the possible outcomes of their genetic testing.

The expansion of prenatal and newborn screening enhances early detection and management of genetic disorders.

The expansion of prenatal and newborn screening significantly enhances the early detection and management of genetic disorders by enabling the identification of abnormalities before or shortly after birth. Prenatal screening enables parents and medical professionals to plan for required interventions and make precise decisions about managing the pregnancy. The improved screening programs encourage early genetic counseling and support the services by increasing awareness among families. The early management strategies include dietary improvements and medicines that help tailor the genetic problem.

Industry Experts Opinion

“Early diagnosis and treatment of the condition can greatly enhance outcomes and stop permanent visual loss. Healthcare providers and patients must understand the genetic basis of glaucoma and take preventative measures to slow its progression.”

• Dr Deven Tuli, Consultant Glaucoma, AIIMS.

"The current market is very small because of the challenges like cost, awareness etc. But the potential is huge because we are one of the largest populated countries in the world and secondly, we have a huge burden of inherited disorders. This can be attributed to our population history where we divided ourselves into small population groups and allowing inbreeding within the group and consanguinity, across multiple generations, leading to higher baggage of genetic diseases”

• Sam Santhosh, Chairman, MedGenome.

Segment Analysis

The Genetic Testing Market is segmented based on Product, Testing, Techniques, Disease, Sample Type, and Regions.

Based on the product, the genetic testing market has been classified into Consumables, Kits and Reagents, and Software. Kits and Reagents are crucial components in genetic testing. Provide the necessary tools for conducting tests such as DNA extraction and amplification. It ensures that the test is reliable and accurate, which makes it dominant in the product category.

Based on the techniques, the genetic testing market has been classified into Polymerase chain reaction, Next-generation sequencing, DNA sequencing, and Microarray analysis. Next-generation gene sequencing (NGS) is a cutting-edge technique that allows rapid and comprehensive analysis of multiple genes. Provides high accuracy and reliability of the results. This technique is widely used in gene testing due to its efficiency in diagnosing complex genetic disorders. 

Regional Analysis

Regionally, the genetic testing market is exhibited across North America and Europe. In North America, the genetic testing market is growing rapidly due to the best healthcare infrastructure, and the high adoption rates of innovative technology. Genetic testing techniques now become integral in the diagnosis of rare genetic diseases. Europe is the second-largest market for genetic testing. The European countries adopt a wide range of applications for cancer diagnosis and rare disease management. This market focuses on personalized medicines.

Competitive Landscape

The genetic testing market is highly competitive. The market is growing with technological advancements and the increasing demand for personalized medicine. The key players in the market include MedGenome Labs Limited, Strand Life Sciences Pvt Ltd., and Centogene India Private Limited. This company is known for its advanced gene testing technologies. They are continuously engaged in introducing innovation into the market. Regulation changes have an impact on the market's competitive environment as well. For instance, in January 2024, the National Health Service (NHS) of the United Kingdom (UK) is credited with inventing the 'blood matching' genetic test, which established a global standard for personalized healthcare for people with sickle cell disease and thalassemia.

Genetic Testing Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In March 2024, Pinnacle Fertility, a well-known network of exceptional clinics that specialize in family-building, announced a strategic partnership with LabCorp, a well-known worldwide supplier of state-of-the-art, comprehensive laboratory solutions.
• In February 2024, CooperSurgical and Fulgent collaborated to create genetic screening panels for newborns. CooperSurgical's Cord Blood Registry (CBR) will offer genetic testing options via Fulgent's Picture Genetics platform through this partnership.

Report Coverage:

By Product

• Consumables
• Kits and Reagents
• Software

By Testing

• Nutrigenomic Testing
• Pharmacogenomic Testing
• Predictive Testing and Presymptomatic Testing
• Prenatal and Newborn Testing
• Forensic Testing
• Others

By Techniques

• Polymerase chain reaction
• Next-Generation Sequencing
• DNA sequencing
• Microarray Analysis
• Others

By Disease

• Alzheimer's Disease
• Cystic Fibrosis
• Cancer
• Arrhythmias
• Down syndrome
• Others

By Sample Type

• Blood Sample
• Saliva Sample
• Tissue Sample
• Other samples

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• MedGenome Labs Limited
• Strand Life Sciences Pvt Ltd.
• Centogene India Private Limited
• Eurofins Genomics India Pvt Ltd.
• Mapmygenome India Limited
• ClevergeneBiocorp Private Limited
• LifeCell International Pvt. Ltd.
• Genes2Me Pvt. Ltd.
• GeneTech India Private Limited
• DNA Forensics Laboratory Pvt. Ltd.
• Lilac Insights
• Xcode Life
• Positive Bioscience
• GenePath Diagnostics
• Core Diagnostics

Frequently Asked Questions (FAQs)